Search Within

CTCR Scholars

Formats
  1. Meeting Abstract (873)
  2. Journal Article (564)
  3. Review (72)
  4. Research Letter (38)
  5. Editorial (29)
  6. Correspondence (24)
  7. Miscellaneous (17)
  8. Book Section (11)
  9. Guidelines (7)
  10. Conference Paper (4)
Groups
  1. Department of Medicine (1415)
  2. Hematologic Malignancies, Division of (1082)
  3. MSK Grad Students (1018)
  4. Center for Hematologic Malignancies (985)
  5. Master of Science in Clinical and Translational Cancer Research (983)
  6. Survivorship Research (917)

More Groups

People
  1. Sergio Giralt (553)
  2. Miguel-Angel Perales (411)
  3. Michael Scordo (385)
  4. Gunjan Shah (341)
  5. Sean Devlin (333)
  6. Parastoo Dahi (305)

More People

Years
  1. 2025 (98)
  2. 2024 (251)
  3. 2023 (261)
  4. 2022 (230)
  5. 2021 (166)
  6. 2020 (211)

More Years

Publications
  1. Blood (318)
  2. Biology of Blood and Marrow Transplantation (187)
  3. Journal of Clinical Oncology (144)
  4. Annals of Surgical Oncology (83)
  5. Bone Marrow Transplantation (65)
  6. Transplantation and Cellular Therapy (56)

More Publications

Publishers
  1. Elsevier Inc. (390)
  2. American Society of Hematology (372)
  3. American Society of Clinical Oncology (158)
  4. Nature Publishing Group (134)
  5. Springer (102)
  6. American Association for Cancer Research (65)

More Publishers

Results (1639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Impact of adjuvant chemotherapy on resected intraductal papillary mucinous neoplasm-derived pancreatic cancer: Results from an international multicenter study
    Journal Article

    Habib, J. R.; Kinny-Köster, B.; Javed, A. A.; Zelga, P.; Saadat, L. V.; Kim, R. C.; Gorris, M.; Allegrini, V.; Watanabe, S.; Sharib, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • KRAS variants are associated with survival outcomes and genomic alterations in biliary tract cancers
    Journal Article

    Gelfer, R.; Gulla, A.; Kalvin, H. L.; Song, Y.; Harding, J.; Abou-Alfa, G. K.; O'Reilly, E. M.; Park, W.; Chandwani, R.; Wei, A.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • The promises and potential pitfalls of pharmacokinetic model–based dosing in cellular therapy
    Correspondence

    Scordo, M.
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Model-based dosing for better survival after transplantation
    Editorial

    Boelens, J. J.; Scordo, M.
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
    Meeting Abstract

    Weisel, K.; Mina, R.; Mylin, A.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M.; Shune, L.; Isufi, I.; Harrison, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save